Nepuvibart (ZRC3308-B10) is a monoclonal antibody of the IgG1 subtype, designed specifically to target SARS-CoV-2. It exhibits high binding affinity to a distinct, non-competing epitope located on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. For enhanced therapeutic efficacy, Nepuvibart can be administered in conjunction with ZRC3308-A7 in a 1:1 ratio. This combination has been shown to be effective in the prevention of COVID-19, as well as in the treatment of the early stages of the disease prior to the onset of severe symptoms.
Nepuvibart (ZRC3308-B10) is a monoclonal antibody of the IgG1 subtype, designed specifically to target SARS-CoV-2. It exhibits high binding affinity to a distinct, non-competing epitope located on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. For enhanced therapeutic efficacy, Nepuvibart can be administered in conjunction with ZRC3308-A7 in a 1:1 ratio. This combination has been shown to be effective in the prevention of COVID-19, as well as in the treatment of the early stages of the disease prior to the onset of severe symptoms.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
